HIV infection: Future perspectives for a 'fatal' disease?;L'infection VIH: Perspectives d'avenir pour une maladie dite fatale?

Schweizerische Medizinische Wochenschrift

Volumn 127, Issue 13, 1997, Pages 521-527

  Von Overbeck, J ^a   Iten, A ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DIDANOSINE; FLUCONAZOLE; INDINAVIR; LAMIVUDINE; PROTEINASE INHIBITOR; RIFABUTIN; RIFAMPICIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ANEMIA; CONFERENCE PAPER; DIARRHEA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOPENIA; LYMPHOCYTE COUNT; NEUROPATHY; PANCREATITIS; VIRUS LATENCY; VIRUS REPLICATION;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; PATIENT COMPLIANCE; PATIENT EDUCATION; RESEARCH; VIRAL LOAD; VIRUS REPLICATION;

EID: 0030934493     PISSN: 00367672     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (16)

1. Corey L, Holmes KK: Therapy for human immunodeficiency virus infection - what have we learned? N Engl J Med 1996; 335: 1142-1143.
2. Sous-commission «clinique» de la commission fédérale sur les questions liées au SIDA. Directives pour l'utilisation des médicaments antiviraux dans le traitement de l'infection par le VIH. Bull OFSP 1996; 29: 5-7.
3. Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM et al.: Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. JAMA 1996; 276: 146-154.
4. Kinloch-de Loës S, Hirschel BJ, Hoen C, Cooper DA, Tindall B et al.: A controlled trial of zidovudine in primary human immunodeficiency virus infection. N Engl J Med 1995; 333: 408-413.
5. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD: HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996; 271: 1582-1586.
6. Pantaleo G, Menzo S, Vaccarezza M, Graziosi C, Cohen OJ et al.: Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. N Engl J Med 1995; 332: 209-216.
7. Mellors JW, Rinaldo CR, Gupta P, White RM, Todd JA et al.: Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996; 272: 1167-1170.
8. Saag MS, Holodniy M, Kuritzkes DR, O'Brien WA, Coombs R et al.: HIV viral load markers in clinical practice. Nature Med 1996; 2: 625-629.
9. + lymphocytes counts and the risk of progression to AIDS. N Engl J Med 1996; 334: 426-431.
10. Havlir D, Richmann DD: Viral dynamics of HIV: implications for drug development and therapeutic strategies. Ann Intern Med 1996; 124: 984-994.
11. Danner SA, Carr A, Leonard JM, Lehman LM, Gudiol F et al.: A short-term study of the safety, pharmacokinetics and efficacy of ritonavir, an inhibitor of HIV-1 protease. N Engl J Med 1995; 333: 1528-1533.
12. Delta Coordinating committee: Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996; 348: 283-291.
13. Hammer SM, Katzenstein DA, Hughes MD, Gundacker H, Schooley RT et al.: A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996; 335: 1081-1090.
14. Katzenstein DA, Hammer SM, Hughes MD, Grundacker H, Jackson JB et al: The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. N Engl J Med 1996; 335: 1091-1098.
15. + T-cell counts in HIV-infected patients. Ann Intern Med 1996; 124: 1039-1050.
16. Pantaleo G, Cohen OJ, Schwartzentruber DJ, Graziosi C, Vaccarezza M, Fauci AS: Pathogenic insights from studies of lymphoid tissue from HIV-infected individuals. J AIDS 1995; 10 (Suppl. 1): S6-S14.